Aims: The aim of this study was to estimate the prevalence of psychiatric disorders among 1439 heavy cannabis users seeking treatment for abuse problems in Denmark.
Design: Using two different registers, we compared cannabis users with 9122 abusers of other substances.
Findings: (1). Cannabis users were younger and more often males, but otherwise demographic data suggested that the group was as marginalized as users of hard drugs. (2). Additional abuse of other substances was common. (3). Even though cannabis users were generally young, 27.5% had at some point been inpatients at psychiatric hospitals with disorders unrelated to psychoactive substance abuse. (4). Cannabis users had significantly raised levels of depression (p < 0.001) and personality disorders (p < 0.0001) compared with users of other drugs, while the prevalence of schizophrenia was marginally raised (p < 0.05). The results were obtained after adjustment for age, gender and secondary abuse. Analyses were made using logistic regression methods.
Conclusion: Co-morbid psychiatric disorders are common among heavy cannabis users seeking treatment. Some psychiatric disorders occur more frequently in this group compared with users of other substances.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00127-004-0719-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging trends in cannabis administration for women with chronic pain.
Mental Health Sci
December 2024
School of Psychology, Fielding Graduate University, Santa Barbara, California, USA.
Cannabis use among women who experience chronic pain is on the rise in the United States. However, little is known about women's motives and preferences for cannabis administration. The purpose of this study was to characterize cannabis use among women with chronic pain.
View Article and Find Full Text PDFCannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiques.
Can J Psychiatry
January 2025
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Objectives: To establish whether the risk of psychotic disorders in cannabis users changes with time following cannabis cessation using data from the European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI) case-control study.
Methods: The EU-GEI case-control study collected data from first episode psychosis patients and population controls across sites in Europe and Brazil between May 2010 and April 2015. Adjusted logistic regressions were applied to examine whether the odd of psychosis case status changed: (1) with time following cannabis cessation and (2) across different cannabis use groups.
Cannabis use and atherosclerotic cardiovascular disease outcomes: A meta-analysis of multinational cohort data.
Dis Mon
January 2025
Department of Internal Medicine, Trinity Health Oakland/ Wayne State University, Pontiac, Michigan, USA.
Background: While an association between cannabis use and the risk of atherosclerotic cardiovascular diseases (ASCVD) has been reported numerous times, it remains inconclusive as to whether this link is causal in nature. We sought to consolidate data from observational studies to explore the association between ever use of cannabis and ASCVD outcomes, including myocardial infarction, stroke, and a combined measure of any adverse cardiovascular events in comparison to non-users or controls.
Methods: We performed a systematic literature search on PubMed, Scopus, ScienceDirect, and Cochrane Library for relevant studies from inception until April 2024.
Renal Outcomes and Other Adverse Effects of Cannabinoid Supplementation.
Nutrients
December 2024
Department of Nephrocardiology, Medical University of Lodz, 90-549 Lodz, Poland.
This narrative review explores the benefits and risks of cannabinoids in kidney health, particularly in individuals with pre-existing renal conditions. It discusses the roles of cannabinoid receptor ligands (phytocannabinoids, synthetic cannabinoids, and endocannabinoids) in kidney physiology. The metabolism and excretion of these substances are also highlighted, with partial elimination occurring via the kidneys.
View Article and Find Full Text PDFPatients' Health-Related Quality of Life and Use of Medicinal Cannabis: A Cross-Sectional Survey Study.
Drugs Real World Outcomes
January 2025
Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.
Background: Studies on medicinal cannabis (MC) have primarily investigated effects on diseases and symptoms, while there is only sparse knowledge on patients' health-related quality of life. Our aim was, firstly, to compare the health-related quality of life of patients (MC users and non-users) within four specified diagnostic indications (multiple sclerosis, paraplegia, neuropathy, and nausea and vomiting after chemotherapy) with that of patients with other diagnostic indications (MC users only) and the adult population (non-users only). Secondly, we estimate the associations between use of MC and health-related quality of life for patients in the four specified diagnostic indications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!